Clinic
Pro-Care Family Health of Oklahoma , LLC
Pro-Care Family Health of Oklahoma , LLC was paid $865K by Medicaid between Apr 2018 and Dec 2024, across 33 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 73% of everything it billed.
33Billing provider infoPRO-CARE FAMILY HEALTH OF OKLAHOMA , LLC
POTEAU, OK 74953
POTEAU, OK 74953
33aNPI1396234761assigned 05/01/2018
33bProvider typeMedical Specialty Clinic/Center
28Total paid$865K
24GClaims22,261
24DCodes billed33
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other Medical Specialty Clinic/Center providers in Oklahoma
Rank by total paid#40 of 90
Median peer was paid$602K
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,188 | $77K | |
| 2019 | 169 | $12K | |
| 2020 | 326 | $18K | |
| 2021 | 3,006 | $100K | |
| 2022 | 4,621 | $198K | |
| 2023 | 6,188 | $220K | |
| 2024incomplete | 6,763 | $241K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 73% | 10,323 | 9,792 | $633K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 14% | 2,246 | 2,086 | $118K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 329 | 311 | $20K |
| 99406 | 1.8% | 1,222 | 1,180 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 281 | 273 | $14K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.5% | 251 | 244 | $13K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.1% | 93 | 80 | $10K |
| 96132 | 1.0% | 220 | 220 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 539 | 521 | $8K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 62 | 60 | $8K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 288 | 281 | $6K |
| 97597 | <1% | 180 | 177 | $3K |
21 more codes
| 96138 | <1% | 226 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 24 | $2K |
| 11750 | <1% | 55 | $1K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 16 | $1K |
| 11721 | <1% | 115 | $850.13 | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 123 | $766.89 |
| 36415 | Collection of venous blood by venipuncture | <1% | 119 | $525.57 |
| 20551 | <1% | 74 | $295.54 | |
| 80306 | <1% | 15 | $185.33 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 213 | $116.55 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 17 | $68.57 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 210 | $54.03 |
| 3074F | <1% | 1,711 | $0.01 | |
| 3079F | 0% | 615 | $0.00 | |
| 1125F | 0% | 382 | $0.00 | |
| 3075F | 0% | 127 | $0.00 | |
| 3080F | 0% | 36 | $0.00 | |
| 3008F | 0% | 333 | $0.00 | |
| 3078F | 0% | 1,548 | $0.00 | |
| 3077F | 0% | 256 | $0.00 | |
| 99072 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOOLY, CHRIS (MEMBER)
| Provider | Location | Paid |
|---|---|---|
| Pro-Care Family Health of Arkansas, LLC | Bonanza, AR | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.